2025
Racial and ethnic disparities in conversion to mastectomy following lumpectomy
Khubchandani J, KC M, Dey P, Proussaloglou E, Valero M, Berger E, Park T, Gross C, Butler P, Fayanju O, Winer E, Golshan M, Greenup R. Racial and ethnic disparities in conversion to mastectomy following lumpectomy. Breast Cancer Research And Treatment 2025, 211: 99-110. PMID: 39937397, DOI: 10.1007/s10549-025-07625-6.Peer-Reviewed Original ResearchConceptsConversion to mastectomyNeoadjuvant chemotherapyBreast conservationStage 0-III breast cancerWhite womenBreast cancerBlack womenBreast cancer careNational Cancer DatabaseMultivariate logistic regression modelEvaluate contemporary trendsLogistic regression modelsCancer careImprove disparitiesEthnic disparitiesDiagnosis yearInitial lumpectomySocio-demographicCancer DatabaseClinical factorsMastectomyLumpectomySurgeryResultsThe studyTreatment sequence
2024
Multimodality Imaging of Postmastectomy Breast Reconstruction Techniques, Complications, and Tumor Recurrence.
Thai J, Sodagari F, Colwell A, Winograd J, Revzin M, Mahmoud H, Mozayan S, Chou S, Destounis S, Butler R. Multimodality Imaging of Postmastectomy Breast Reconstruction Techniques, Complications, and Tumor Recurrence. RadioGraphics 2024, 44: e230070. PMID: 38573814, DOI: 10.1148/rg.230070.Peer-Reviewed Original ResearchConceptsTumor recurrencePostoperative evaluation of patientsFlap reconstruction methodsImplant-based reconstructionMultimodal imagingBreast reconstruction techniquesFat graft placementBreast cancer recurrenceTissue flap reconstructionEvaluation of patientsNipple-sparing techniquesTissue donor sitesFlap-based reconstructionNipple-areolar complex reconstructionDiagnostic breast imagingUnique patient populationAutologous tissue flapsAbnormal imaging appearancesBreast cancer screeningMastectomy optionLocal recurrenceOncoplastic surgeryDisease recurrenceFlap reconstructionReconstructed breastThe Present and Future of Postmastectomy Radiation
Ohri N, George M, Omene C, Haffty B. The Present and Future of Postmastectomy Radiation. International Journal Of Radiation Oncology • Biology • Physics 2024, 118: 466-467. PMID: 38220259, DOI: 10.1016/j.ijrobp.2023.10.002.Peer-Reviewed Original Research
2023
Patient Preferences for Postmastectomy Breast Reconstruction
Shammas R, Hung A, Mullikin A, Sergesketter A, Lee C, Reed S, Fish L, Greenup R, Hollenbeck S. Patient Preferences for Postmastectomy Breast Reconstruction. JAMA Surgery 2023, 158: 1285-1292. PMID: 37755818, PMCID: PMC10535024, DOI: 10.1001/jamasurg.2023.4432.Peer-Reviewed Original ResearchConceptsRisk of complicationsBreast reconstructionAbdominal morbidityFlap reconstructionBreast cancerGenetic predispositionPatient-physician discussionsImplant-based reconstructionPostmastectomy breast reconstructionCross-sectional studyChance of complicationsPatient-centered careAdditional operationsHigher educational levelMajor complicationsPreoperative counselingPatient preferencesFlap appearanceTreatment preferencesImplant reconstructionMAIN OUTCOMENew diagnosisPatient valuesComplicationsMean increaseRadiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial
Jagsi R, Barlow W, Woodward W, Connolly E, Mahtani R, Shumway D, Speers C, Stecklein S, Zeidan Y, Zhang H, Sharma P, Pusztai L, Hortobagyi G, Kalinsky K. Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial. JAMA Oncology 2023, 9: 1083-1089. PMID: 37410451, PMCID: PMC10326730, DOI: 10.1001/jamaoncol.2023.1984.Peer-Reviewed Original ResearchConceptsInvasive disease-free survivalDisease-free survivalLocoregional recurrenceBreast-conserving surgeryBreast cancerLocoregional therapyCumulative incidenceRecurrence scoreRadiotherapy informationERBB2-negative breast cancerPredictors of LRRRate of LRRSecondary analysisNode-positive breast cancerBreast Recurrence ScoreLimited nodal diseaseLower locoregional recurrenceOmission of chemotherapyAxillary surgeryRadiotherapy receiptEndocrine therapyN1 diseaseNodal diseaseLocoregional treatmentMenopausal statusRisk of Squamous Cell Carcinoma of the Breast Following Postmastectomy Implant Reconstruction in Women With Breast Cancer and Carcinoma in Situ
Kinslow C, Yu J, DeStephano D, Kachnic L, Cheng S, Neugut A, Horowitz D. Risk of Squamous Cell Carcinoma of the Breast Following Postmastectomy Implant Reconstruction in Women With Breast Cancer and Carcinoma in Situ. JAMA Surgery 2023, 158: 769-771. PMID: 37074722, PMCID: PMC10116379, DOI: 10.1001/jamasurg.2023.0262.Peer-Reviewed Original ResearchASO Author Reflections: Ancillary Treatment After Breast Cancer Surgery: Who are We Missing?
Chan V, Heller D, Sanft T. ASO Author Reflections: Ancillary Treatment After Breast Cancer Surgery: Who are We Missing? Annals Of Surgical Oncology 2023, 30: 5649-5650. PMID: 37179270, DOI: 10.1245/s10434-023-13507-2.Peer-Reviewed Original Research
2022
Flap to Mastectomy Mass: Are Higher Ratios Associated with Greater Breast Reconstruction Satisfaction?
Long AS, Ching A, Hauc SC, Mozaffari MA, Junn AH, Rivera JC, Almeida MN, Alper DP, Allam O, Alperovich M. Flap to Mastectomy Mass: Are Higher Ratios Associated with Greater Breast Reconstruction Satisfaction? Journal Of Reconstructive Microsurgery 2022, 39: 209-213. PMID: 35752166, DOI: 10.1055/a-1885-1540.Peer-Reviewed Original ResearchConceptsBREAST-Q surveysAutologous breast reconstructionBody mass indexPatient satisfactionBreast reconstructionHigh patient-reported satisfactionLong-term patient satisfactionPatient underwent radiation therapySuperior patient-reported outcomesDeep inferior epigastric perforator flapPatient-reported satisfactionUnderwent radiation therapyPatient-reported outcomesNumber of surgeriesMost patientsMass indexRetrospective studySurgery failureBreast ScoreRadiation therapySmall breastsPerforator flapProsthetic techniquesBreast sizePatientsEditorial Comment on: One-Year Experience of Same-Day Mastectomy and Breast Reconstruction Protocol
Kim LS, Park T, Berger ER, Golshan M, Greenup RA. Editorial Comment on: One-Year Experience of Same-Day Mastectomy and Breast Reconstruction Protocol. Annals Of Surgical Oncology 2022, 29: 5361-5363. PMID: 35834143, PMCID: PMC9281278, DOI: 10.1245/s10434-022-12021-1.Peer-Reviewed Original ResearchRacial and Ethnic Disparities in Surgical Outcomes after Postmastectomy Breast Reconstruction.
Sarver MM, Rames JD, Ren Y, Greenup RA, Shammas RL, Hwang ES, Hollenbeck ST, Hyslop T, Butler PD, Fayanju OM. Racial and Ethnic Disparities in Surgical Outcomes after Postmastectomy Breast Reconstruction. Journal Of The American College Of Surgeons 2022, 234: 760-771. PMID: 35426388, PMCID: PMC9347225, DOI: 10.1097/xcs.0000000000000143.Peer-Reviewed Original ResearchConceptsLength of stayLonger LOSPostmastectomy breast reconstructionPostoperative complicationsWhite womenBreast reconstructionBreast cancerNational Inpatient Sample databasePost-mastectomy reconstructionType of reconstructionRace/ethnicityPerioperative comorbiditiesPreoperative comorbiditiesComorbidity scorePerioperative complicationsPerioperative factorsPatient demographicsPerioperative outcomesSurgical complicationsComorbid conditionsSurgical outcomesPostmastectomy reconstructionMicrosurgical complicationsPrimary careAutologous reconstructionPerioperative magnetic resonance imaging in breast cancer care: Distinct adoption trajectories among physician patient-sharing networks
Xu X, Soulos PR, Herrin J, Wang SY, Pollack CE, Killelea BK, Forman HP, Gross CP. Perioperative magnetic resonance imaging in breast cancer care: Distinct adoption trajectories among physician patient-sharing networks. PLOS ONE 2022, 17: e0265188. PMID: 35290417, PMCID: PMC8923453, DOI: 10.1371/journal.pone.0265188.Peer-Reviewed Original ResearchConceptsPhysician patient-sharing networksPerioperative magnetic resonance imagingClinical risk factorsMagnetic resonance imagingPatient clinical risk factorsPatient-sharing networksBreast cancer careRisk-adjusted ratesMastectomy usePhysician networksCancer careRisk factorsEnd Results-Medicare databaseCharacteristics of patientsProportion of patientsBreast cancer surgeryComposition of patientsMRI adoptionDistinct trajectoriesMore patientsCancer surgeryClinical outcomesCancer specialistsMRI usePatientsDoes Breast Cancer Subtype Impact Margin Status in Patients Undergoing Partial Mastectomy?
Horattas I, Fenton A, Gabra J, Mendiola A, Li F, Namm J, Solomon N, Gass J, Lum S, Murray M, Howard-McNatt M, Dupont E, Levine E, Brown E, Ollila D, Chiba A, Chagpar AB. Does Breast Cancer Subtype Impact Margin Status in Patients Undergoing Partial Mastectomy? The American Surgeon 2022, 88: 1607-1612. PMID: 34982015, DOI: 10.1177/00031348211069783.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsFemaleHumansMargins of ExcisionMastectomyMastectomy, SegmentalReceptor, ErbB-2ConceptsCavity shave marginsMargin statusPartial mastectomyMolecular subtypesBreast cancer stage IOverall positive margin rateStandard partial mastectomyBreast-conserving therapyCancer stage IInvasive breast cancerImpact of subtypePositive margin rateBreast cancer subtypesLymphovascular invasionSurgical therapySystemic therapyRandomized trialsSurgical marginsShave marginsInvasive carcinomaMargin rateBreast cancerHispanic ethnicityStage IPatientsLocal Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer
Bellon JR, Tayob N, Yang DD, Tralins J, Dang CT, Isakoff SJ, DeMeo M, Burstein HJ, Partridge AH, Winer EP, Krop IE, Tolaney SM. Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer. International Journal Of Radiation Oncology • Biology • Physics 2022, 113: 117-124. PMID: 34990776, DOI: 10.1016/j.ijrobp.2021.12.173.Peer-Reviewed Original ResearchConceptsHER2-positive breast cancerBreast-conserving surgeryStage I HER2-positive breast cancerT-DM1 armBreast radiation therapyT-DM1Radiation therapySkin toxicityBreast cancerBCS patientsWBRT patientsInvasive disease-free survival eventsDisease-free survival eventsInvasive disease-free survivalHuman epidermal growth factor receptor 2Phase II Randomized TrialWhole breast radiation therapyEpidermal growth factor receptor 2Adjuvant T-DM1Adjuvant trastuzumab emtansineEfficacy of HER2RT-related toxicityWeeks of therapyAcute skin toxicityAnti-HER2 therapy
2021
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, Fox P, Wolff AC, Chan A, Winer EP, Pfeiler G, Miller KD, Colleoni M, Suga JM, Rubovsky G, Bliss JM, Mayer IA, Singer CF, Nowecki Z, Hahn O, Thomson J, Wolmark N, Amillano K, Rugo HS, Steger GG, de Aránguiz B, Haddad TC, Perelló A, Bellet M, Fohler H, Filho O, Jallitsch-Halper A, Solomon K, Schurmans C, Theall KP, Lu DR, Tenner K, Fesl C, DeMichele A, Mayer EL, groups and investigators O. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). Journal Of Clinical Oncology 2021, 40: 282-293. PMID: 34874182, PMCID: PMC10476784, DOI: 10.1200/jco.21.02554.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantDisease ProgressionDisease-Free SurvivalFemaleHumansMastectomyMiddle AgedNeoadjuvant TherapyNeoplasm StagingPiperazinesProgression-Free SurvivalProspective StudiesProtein Kinase InhibitorsPyridinesTime FactorsConceptsHormone receptor-positive breast cancerInvasive disease-free survivalReceptor-positive breast cancerAdjuvant endocrine therapyCancer-free survivalEndocrine therapyEarly breast cancerBreast cancerAdjuvant palbociclibPALLAS trialEnd pointEarly hormone receptor-positive breast cancerBreast cancer-free survivalDistant recurrence-free survivalHuman epidermal growth factor receptorProtocol-defined analysisStandard endocrine therapyPrimary end pointSecondary end pointsAdvanced breast cancerDisease-free survivalNew safety signalsRecurrence-free survivalEvent end pointsCyclin-dependent kinase 4The Impact of implant-based reconstruction on persistent pain after breast cancer surgery: A systematic review
Guliyeva G, Torres RA, Avila FR, Kaplan JL, Lu X, Forte AJ. The Impact of implant-based reconstruction on persistent pain after breast cancer surgery: A systematic review. Journal Of Plastic Reconstructive & Aesthetic Surgery 2021, 75: 519-527. PMID: 34801428, DOI: 10.1016/j.bjps.2021.09.079.Peer-Reviewed Original ResearchMeSH KeywordsBreast ImplantationBreast ImplantsBreast NeoplasmsChronic PainFemaleHumansMammaplastyMastectomyConceptsBreast cancer surgeryPersistent painCancer surgeryFrequency of analgesicsPlastic surgeonsBreast cancer survivorsFull-text articlesAppropriate reconstruction techniqueCancer survivorsSurgical techniqueImplant reconstructionEligible articlesSystematic reviewPPBCTFinal reviewSame dosagePatientsRelevant articlesIncreased chanceLower chancePainSurgerySurgeonsMost studiesScopus databasesComparison of Autologous Breast Reconstruction Complications by Type of Neoadjuvant Chemotherapy Regimen
Olawoyin OM, Mehta S, Chouairi F, Gabrick KS, Avraham T, Pusztai L, Alperovich M. Comparison of Autologous Breast Reconstruction Complications by Type of Neoadjuvant Chemotherapy Regimen. Plastic & Reconstructive Surgery 2021, 148: 1186-1196. PMID: 34644277, DOI: 10.1097/prs.0000000000008505.Peer-Reviewed Original ResearchConceptsNeoadjuvant chemotherapy regimensMicrovascular breast reconstructionNeoadjuvant chemotherapyChemotherapy regimensComplication rateFat necrosisBreast reconstructionImmune cellsCLINICAL QUESTION/LEVELMultivariate binary logistic regressionYale-New Haven HospitalAdministration of taxanesBreast Reconstruction ComplicationsInclusion of anthracyclinesNeoadjuvant chemotherapy regimenDosage of chemotherapyNew Haven HospitalNeoadjuvant chemotherapy completionLogistic regression modelsBinary logistic regressionOncologic historyTaxane administrationChemotherapy regimenChemotherapy completionPathologic responseAlliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer
O'Sullivan CC, Ballman KV, McCall L, Kommalapati A, Zemla T, Weiss A, Mitchell M, Blinder V, Tung NM, Irvin WJ, Lee M, Goetz MP, Symmans WF, Borges VF, Krop I, Carey LA, Partridge AH. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncology 2021, 17: 4665-4676. PMID: 34636255, PMCID: PMC8600597, DOI: 10.2217/fon-2021-0753.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAdultAntineoplastic Combined Chemotherapy ProtocolsBrain NeoplasmsBreastBreast NeoplasmsChemoradiotherapy, AdjuvantChemotherapy, AdjuvantClinical Trials, Phase III as TopicDisease-Free SurvivalDouble-Blind MethodFemaleFollow-Up StudiesHumansMastectomyMiddle AgedMulticenter Studies as TopicNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm, ResidualOxazolesPlacebosProspective StudiesPyridinesQuinazolinesRandomized Controlled Trials as TopicReceptor, ErbB-2ConceptsInvasive disease-free survivalDisease-free survivalBrain metastasis-free survivalBreast cancer-free survivalDistant recurrence-free survivalT-DM1Overall survivalResidual diseaseHER2-positive invasive breast cancerAdjuvant T-DM1Cancer-free survivalRecurrence-free survivalInvasive breast cancerMetastasis-free survivalPharmacokinetic end pointsOutcomes of interestQuality of lifeEligible patientsAdjuvant radiotherapyEndocrine therapyNeoadjuvant chemotherapyCorrelative biomarkersCare guidelinesBreast cancerPlaceboSurgical Management of Hereditary Breast Cancer
Berger ER, Golshan M. Surgical Management of Hereditary Breast Cancer. Genes 2021, 12: 1371. PMID: 34573353, PMCID: PMC8470490, DOI: 10.3390/genes12091371.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsChemopreventionFemaleGenetic Predisposition to DiseaseGenetic TestingHereditary Breast and Ovarian Cancer SyndromeHeterozygoteHumansMastectomyMutationPractice Guidelines as TopicProphylactic Surgical ProceduresSalpingo-oophorectomyConceptsHereditary breast cancerBreast cancerGenetic variant carriersSurgical risk reductionSurgical management optionsSurgical managementBreast/ovarian cancer susceptibility geneOvarian cancer susceptibility genesVariant carriersCancer susceptibility genesGenetic testingCancer treatmentCancerRisk reductionSusceptibility genesManagement optionsPersistent Disparities in Postmastectomy Breast Reconstruction and Strategies for Mitigation
Butler PD, Morris MP, Momoh AO. Persistent Disparities in Postmastectomy Breast Reconstruction and Strategies for Mitigation. Annals Of Surgical Oncology 2021, 28: 6099-6108. PMID: 34287788, DOI: 10.1245/s10434-021-10487-z.Peer-Reviewed Original ResearchMeSH KeywordsBlack or African AmericanBreast NeoplasmsFemaleHealthcare DisparitiesHumansMammaplastyMastectomyConceptsAfrican American womenPostmastectomy breast reconstructionBreast reconstructionReconstructive optionsBreast cancer care continuumAmerican womenRacial disparitiesPhysician referral patternsMore risk factorsStandard of careCancer care continuumBreast reconstruction ratesRacial differencesPersistent racial disparitiesPatient comorbiditiesClinical outcomesReferral patternsPatient knowledgeRisk factorsCare continuumSocial determinantsWhite womenDecision-making satisfactionWomenPersistent disparitiesGenomic features of rapid versus late relapse in triple negative breast cancer
Zhang Y, Asad S, Weber Z, Tallman D, Nock W, Wyse M, Bey JF, Dean KL, Adams EJ, Stockard S, Singh J, Winer EP, Lin NU, Jiang YZ, Ma D, Wang P, Shi L, Huang W, Shao ZM, Cherian M, Lustberg MB, Ramaswamy B, Sardesai S, VanDeusen J, Williams N, Wesolowski R, Obeng-Gyasi S, Sizemore GM, Sizemore ST, Verschraegen C, Stover DG. Genomic features of rapid versus late relapse in triple negative breast cancer. BMC Cancer 2021, 21: 568. PMID: 34006255, PMCID: PMC8130400, DOI: 10.1186/s12885-021-08320-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkers, TumorChemotherapy, AdjuvantDatasets as TopicDisease-Free SurvivalDNA Copy Number VariationsFemaleFollow-Up StudiesGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLogistic ModelsMastectomyMiddle AgedModels, GeneticMutationNeoadjuvant TherapyNeoplasm Recurrence, LocalPrognosisRisk AssessmentTime FactorsTriple Negative Breast NeoplasmsConceptsLate relapseRapid relapseImmune signaturesBreast cancerAnti-tumor CD8 T cellsBackgroundTriple-negative breast cancerTriple-negative breast cancerCD8 T cellsTumor mutation burdenIndependent validation cohortNegative breast cancerFisher's exact testPearson's chi-squared testChi-squared testLogistic regression modelsLuminal signaturePrimary TNBCTNBC subsetImmune subsetsClinical featuresValidation cohortWhole-genome copy numberPrimary tumorM1 macrophagesT cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply